menu search

ALVR / AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel

AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel
The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise. Read More
Posted: Apr 21 2022, 12:47
Author Name: Zacks Investment Research
Views: 103161

ALVR News  

Why AlloVir Stock Dropped Today

By The Motley Fool
September 21, 2023

Why AlloVir Stock Dropped Today

AlloVir stock fell today given concerns over potential selling pressure from a recent lock-up expiration. The lock-up agreement was related to a new s more_horizontal

5 Stocks With Rising P/E to Bet on for Solid Gains

By Zacks Investment Research
August 7, 2023

5 Stocks With Rising P/E to Bet on for Solid Gains

Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Crocs (CROX), AlloVir (ALVR), Arcadia Biosciences (RK more_horizontal

5 Top-Ranked Stocks With Rising P/E Worth Investing In

By Zacks Investment Research
July 21, 2023

5 Top-Ranked Stocks With Rising P/E Worth Investing In

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Planet Fitness (PLNT), AlloVir (ALVR), Entergy more_horizontal

Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

By MarketBeat
July 13, 2023

Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

In recent Securities & Exchange Commission filings, Gilead Sciences Inc. NASDAQ: GILD revealed that it had purchased significant stakes in AlloVir Inc more_horizontal

AlloVir: 'Takes One To Know One'

By Seeking Alpha
July 10, 2023

AlloVir: 'Takes One To Know One'

Gilead has purchased $10.9 million in shares of Allovir, a biotech company specializing in cell therapy and organ transplant, giving it a 15% ownershi more_horizontal

AlloVir: Several Late-Stage Programs Make This Worth A Look

By Seeking Alpha
July 1, 2023

AlloVir: Several Late-Stage Programs Make This Worth A Look

Positive final results from the phase 2 study, using posoleucel for BK Virus, were presented at the American Transplant Congress 2023. Discussions wit more_horizontal

AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why

By Zacks Investment Research
June 27, 2023

AlloVir, Inc. (ALVR) Upgraded to Buy: Here's Why

AlloVir, Inc. (ALVR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

Why Shares of AlloVir Plummeted This Week

By The Motley Fool
June 23, 2023

Why Shares of AlloVir Plummeted This Week

AlloVir stock fell to a 52-week low on Thursday. The company's lead therapy has begun phase 3 trials to treat kidney transplant patients who had virus more_horizontal


Search within

Pages Search Results: